Foliglurax

Foliglurax
Clinical data
Other names	DT2331; PXT-002331; PXT-2331
Identifiers
	IUPAC name 4-[3-[4-nitroso-2-(5H-thieno[3,2-c]pyridin-6-ylidene)chromen-6-yl]propyl]morpholine;
CAS Number	1883329-53-0 ; 1883329-51-8 (dihydrochloride);
PubChem CID	135565465;
ChemSpider	59718537;
UNII	FR50CP1D6W;
Chemical and physical data
Formula	C23H23N3O3S
Molar mass	421.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCCC2=CC3=C(C=C2)OC(=C4C=C5C(=CN4)C=CS5)C=C3N=O;
	InChI InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,24H,1-2,6-10H2; Key:XHRLGFLGWZIPEE-UHFFFAOYSA-N;

Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR₄),^[1] which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.^[2]^[3]^[4] It reached phase II clinical trials,^[2] but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.^[5]^[6]